Going forward..., page-349

Re the Chinese investor, might be noteworthy that on December 3rd at the ASH Annual Meeting (American Society of Haematology) in California, there was a presentation on "A Phase I Trial of iPSC-Derived MSCs (CYP-001) in Steroid-Resistant Acute GvHD."

https://ash.confex.com/ash/2018/webprogram/Paper110432.html

Notable participants (titles/qualifications excluded to prevent eye strain), were -

Adrian Bloor, David T Yeung, Igor Slukvin, Kilian Kelly, and John E.J. Rasko.

Gene Therapy expert and clinical heamatologist Prof John Rasko heads the University of Sydney's newly established Li Ka-Shing Cell and Gene Therapy Initiative.